Galecto, Inc. Files 2023 Annual Report on Form 10-K

TL;DR

<b>Galecto, Inc. has filed its annual 10-K report for the fiscal year ending December 31, 2023.</b>

AI Summary

Galecto, Inc. (DMRA) filed a Annual Report (10-K) with the SEC on March 8, 2024. Galecto, Inc. filed its 2023 Form 10-K on March 8, 2024. The filing covers the fiscal year ending December 31, 2023. The company's principal executive offices are located at 75 State Street, Suite 100, Boston, MA 02109. Galecto, Inc. is classified under Pharmaceutical Preparations (SIC 2834). The company was formerly known as Galecto Inc. and changed its name on January 16, 2020.

Why It Matters

For investors and stakeholders tracking Galecto, Inc., this filing contains several important signals. This 10-K filing provides a comprehensive overview of Galecto's financial performance, business operations, and risk factors for the fiscal year 2023, crucial for investors to assess the company's current standing and future prospects. The detailed financial statements and disclosures within the 10-K are essential for understanding Galecto's financial health, including its assets, liabilities, and equity, as well as its operational expenses and any potential risks it faces in the pharmaceutical sector.

Risk Assessment

Risk Level: medium — Galecto, Inc. shows moderate risk based on this filing. The company operates in the pharmaceutical sector, which is subject to significant regulatory hurdles, clinical trial risks, and market competition, as indicated by the nature of its business and the typical risks associated with drug development.

Analyst Insight

Review the detailed financial statements and risk factors in the 10-K to understand Galecto's financial position and strategic outlook for the upcoming year.

Key Numbers

• 20231231 — Fiscal Year End (The end date of the reporting period.)
• 20240308 — Filing Date (The date the 10-K was filed.)
• 001-39655 — SEC File Number (The SEC file number for Galecto, Inc.)

Key Players & Entities

• Galecto, Inc. (company) — Filer of the 10-K report.
• 0000950170-24-028610 (other) — Accession number for the filing.
• 20231231 (date) — Conformed period of report.
• 20240308 (date) — Filed as of date.
• 75 State Street, Suite 100, Boston, MA 02109 (address) — Business and mailing address.
• 2834 (other) — Standard Industrial Classification code for Pharmaceutical Preparations.
• Galecto Inc. (company) — Former company name.
• 20200116 (date) — Date of name change.

FAQ

Industry Context

Galecto, Inc. operates within the pharmaceutical preparations industry, focusing on the development of novel therapeutics.

Regulatory Implications

As a pharmaceutical company, Galecto is subject to stringent regulations from health authorities regarding drug development, testing, and approval processes.

What Investors Should Do

1. Analyze the financial statements for revenue, expenses, and cash flow.
2. Review the business description for strategic initiatives and product pipeline updates.
3. Examine the risk factors section for potential challenges and mitigation strategies.

Year-Over-Year Comparison

This is the initial 10-K filing for the fiscal year ending December 31, 2023, following the company's operational period.

Key Financial Figures

• $0.00001 — ch registered Common Stock, par value $0.00001 per share GLTO The Nasdaq Global Se

Filing Documents

• glto-20231231.htm (10-K) — 2369KB
• glto-ex4_2.htm (EX-4.2) — 32KB
• glto-ex10_2.htm (EX-10.2) — 647KB
• glto-ex21_1.htm (EX-21.1) — 8KB
• glto-ex23_1.htm (EX-23.1) — 6KB
• glto-ex31_1.htm (EX-31.1) — 16KB
• glto-ex31_2.htm (EX-31.2) — 16KB
• glto-ex32_1.htm (EX-32.1) — 14KB
• glto-ex97.htm (EX-97) — 35KB
• img109565643_0.jpg (GRAPHIC) — 45KB
• img109565643_1.jpg (GRAPHIC) — 51KB
• img109565643_2.jpg (GRAPHIC) — 184KB
• 0000950170-24-028610.txt (&nbsp;) — 9401KB
• glto-20231231.xsd (EX-101.SCH) — 981KB
• glto-20231231_htm.xml (XML) — 1161KB

Business

Business 1 Item 1A.

Risk Factors

Risk Factors 31 Item 1B. Unresolved Staff Comments 83 Item 1C. Cybersecurity 83 Item 2.

Properties

Properties 83 Item 3.

Legal Proceedings

Legal Proceedings 84 Item 4. Mine Safety Disclosures 84 PART II Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 85 Item 6. Reserved 85 Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 86 Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 98 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 98 Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 98 Item 9A.

Controls and Procedures

Controls and Procedures 98 Item 9B. Other Information 99 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 99 PART III Item 10. Directors, Executive Officers and Corporate Governance 100 Item 11.

Executive Compensation

Executive Compensation 100 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 100 Item 13. Certain Relationships and Related Transactions, and Director Independence 100 Item 14. Principal Accounting Fees and Services 100 PART IV Item 15. Exhibits, Financial Statement Schedules 101 Item 16 Form 10-K Summary 102 i Summary of Material Risks Associated with Our Business Our business is subject to numerous material and other risks and uncertainties that you should be aware of in evaluating our business. These risks include, but are not limited to, the following: We may not be successful in identifying and implementing any strategic business combination, stock or asset acquisition, or other transaction, and any strategic transactions that we may consummate in the future could have negative consequences. If a strategic business combination is not consummated, our board of directors may decide to pursue a dissolution and liquidation. In such an event, the amount of cash available for distribution to our stockholders will depend heavily on the timing of such liquidation as well as the amount of cash that will need to be reserved for commitments and contingent liabilities. We have incurred significant net losses since inception and we expect to continue to incur significant net losses for the foreseeable future. We will require substantial additional capital to finance our operations. If we are unable to raise such capital when needed, or on acceptable terms, we may be forced to delay, reduce and/or eliminate one or more of our research and drug development programs, future commercialization efforts or other operations. Our business is highly dependent on the success of our product candidates GB1211 and GB2064, as well as any other product candidates that we advance into the clinic. All of our product candidates may require significant additional preclinical and clinical development before we may be able to seek reg

Bu siness

Item 1. Bu siness. Overview We are a clinical-stage biotechnology company developing novel small molecule therapeutics that are designed to target the biological processes that lie at the heart of cancer and fibrotic diseases. Our strategy is to focus on diseases without disease-modifying treatment options and where there is a high unmet medical need. We are concentrating on the development of a new class of medicines: small molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2, that target underlying biology for the treatment of multi-factorial diseases like cancer and fibrotic diseases. Galectin proteins, and especially galectin-3, are highly expressed in many cancers, where they promote cancer progression, and fibrotic diseases, where they reduce organ function. The collagen cross-linking enzyme LOXL2 builds the backbone of fibrotic tissue by cross-linking collagen and elastin molecules and has been linked to cancer growth, metastasis and fibrosis. Our product candidates are designed to modulate multiple disease pathways simultaneously by inhibiting the master drivers of the cancer and fibrotic cascades. We believe our galectin and LOXL2 product candidates are distinct from the current generation of anti-cancer and anti-fibrotic agents and have the potential to significantly improve patient outcomes for these complex diseases. In September 2023, we announced a corporate restructuring that resulted in a substantial reduction of our workforce and that we have initiated a process to evaluate strategic alternatives. As part of our ongoing strategic review process, we are exploring potential strategic alternatives that include, without limitation, a stock or asset acquisition, merger, business combination or other transaction. We are also exploring strategic transactions regarding our product candidates and related assets, including, without limitation, licensing transactions and asset sales. We expect to devote substantial time and resources to e

View Full Filing

View this 10-K filing on SEC EDGAR